Open AccessI-SPY 2 Trial Explores Immune Checkpoint Plus PARP Inhibitors in Breast Cancer
Author(s) -
Catlin Nalley
Publication year - 2020
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000669744.85398.82
Subject(s) - medicine , olaparib , breast cancer , oncology , durvalumab , parp inhibitor , paclitaxel , clinical endpoint , triple negative breast cancer , chemotherapy , cancer , cyclophosphamide , clinical trial , immunotherapy , nivolumab , polymerase , poly adp ribose polymerase , gene , biochemistry , chemistry